This article reports on the treatment of a patient with nightmares who was treated with doxazosin of an alpha 1-adrenergic antagonists. A 71-year-old Japanese major depressive disorder (MDD) woman experienced nightmares after the coronavirus disease 2019 pandemic. She had nightmares about being chased by a coronavirus and catching the corona virus. After adding doxazosin 1 mg daily in the morning, her nightmares led to remission without side effects. We also had a rechallenge regimen with doxazosin. The nightmares ceased on the second night of the rechallenge and did not return with continued treatment. This case report suggests that doxazosin may be a useful therapeutic option to target nightmares in individuals with MDD.

中文翻译：

---

多沙唑嗪改善了重度抑郁症患者的COVID-19相关梦night：一例再挑战为阳性的病例报告。

这篇文章报道了噩梦患者的治疗，该患者接受了α1-肾上腺素能拮抗剂多沙唑嗪的治疗。一名71岁的日本严重抑郁症（MDD）妇女在2019年冠状病毒病大流行后经历了噩梦。她梦night以求地被冠状病毒追赶并发现了冠状病毒。每天早晨添加1毫克多沙唑嗪后，她的噩梦导致其缓解而无副作用。我们还接受了多沙唑嗪的再挑战疗法。噩梦在再挑战的第二天就停止了，并且没有继续治疗就返回了。该病例报告表明，多沙唑嗪可能是针对MDD患者梦night的有用治疗选择。